Vericel (NASDAQ:VCEL) Releases Earnings Results

Vericel (NASDAQ:VCEL) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03, Briefing.com reports. The business had revenue of $51.28 million during the quarter, compared to analysts’ expectations of $49.07 million. Vericel had a negative return on equity of 1.55% and a negative net margin of 1.61%. The company’s revenue for the quarter was up 25.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.16) EPS. Vericel updated its FY 2024 guidance to EPS.

Vericel Trading Up 2.0 %

VCEL traded up $0.96 during midday trading on Thursday, hitting $48.65. 318,992 shares of the company traded hands, compared to its average volume of 525,413. Vericel has a 52-week low of $30.18 and a 52-week high of $53.05. The business has a 50 day simple moving average of $47.24 and a two-hundred day simple moving average of $41.61. The company has a market capitalization of $2.35 billion, a price-to-earnings ratio of -540.56 and a beta of 1.74.

Insider Activity at Vericel

In other Vericel news, SVP Sean C. Flynn sold 8,115 shares of the firm’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $45.33, for a total value of $367,852.95. Following the transaction, the senior vice president now owns 167 shares in the company, valued at approximately $7,570.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Sean C. Flynn sold 8,115 shares of the stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $45.33, for a total value of $367,852.95. Following the completion of the sale, the senior vice president now owns 167 shares of the company’s stock, valued at approximately $7,570.11. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Robert L. Md Zerbe sold 3,278 shares of Vericel stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $51.57, for a total transaction of $169,046.46. Following the sale, the director now directly owns 23,395 shares in the company, valued at approximately $1,206,480.15. The disclosure for this sale can be found here. In the last three months, insiders have sold 54,267 shares of company stock valued at $2,450,996. 7.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have commented on VCEL. TheStreet upgraded Vericel from a “d+” rating to a “c-” rating in a research report on Monday, January 29th. HC Wainwright increased their price target on shares of Vericel from $53.00 to $55.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Truist Financial reaffirmed a “buy” rating and issued a $54.00 price objective on shares of Vericel in a report on Tuesday, March 26th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $46.80.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.